IL1B and thrombocytosis disease: In contrast, Ana treatment did not impair myeloid recovery in either young or old 5FU-treated mice, nor did it ameliorate thrombocytosis in old mice (Fig. 6k and Extended Data Fig. 6e), suggesting that it only provides short-term benefits accelerating acute regeneration when given at the height of IL-1 production in the BM niche.